Figure 5.
Therapeutic effect of Ago-125b-5p on MC38 tumor bearing mice models. C57BL/6 J mice were subcutaneously injected with 5×105 MC38 tumor cells each mouse on the right flank on day 1. From day 7, MC38 tumor bearing mice with intratumor injections of Ago-125b-5p or Ago-NC (control) every other day at 2.5 nmol/mouse as indicated for total of five doses. (A) Representative tumor size from each mouse was shown (n=5, each group). (B) The tumor growth curve was plotted (n=5, each group). (C)The tumor bearing mice survival curve (n=10 mice, each group) from two independent experiments. After the last treatment, the tumor tissue, draining lymph nodes and periphery blood serum from each mouse were collected. The tumor tissue and draining lymph nodes were digested and grinded into single cell suspensions as indicated. (D) Summary of the percentage of CD3+ T cells infiltrated in tumor tissue and draining lymph nodes. (E) The ratio of CD8:CD4 T cells in tumor tissue and draining lymph nodes. (F) The serum levels of inflammatory cytokine IL-6, IL-10, MCP-1, TNF, IFNγ and IL-12p70 from Ago-125b-5p treated mouse. The summarized data shown in figure parts D, E, and F were displayed as mean±SEM, n=5 mice of each group. All data were representatives of three separate experiments. By comparison with Ago-NC, *p<0.05, **p<0.01, ***p<0.001, (Student’s t-test).